| Literature DB >> 31466338 |
Silpak Biswas1, Yan Li1, Mohammed Elbediwi1, Min Yue2,3.
Abstract
Antibiotic resistance in bacteria is one of the urgent threats to both public and global health. The Salmonella Typhimurium monophasic sequence type 34 (ST34) clone, with its rapid dissemination and resistance to numerous critical antimicrobials, has raised global concerns. Here, we present an updated overview on the emerging infections caused by mobile colistin resistance (mcr)-carrying colistin-resistant ST34 isolates, covering their global dissemination and virulence-associated efficacy. The higher rates of mcr-1-positive ST34 in children in China highlights the increasing threat caused by this pathogen. Most of the ST34 isolates carrying the mcr-1 gene were isolated from animals and food products, indicating the role of foodborne transmission of mcr-1. The emergence of multidrug resistance genes along with various virulence factors and many heavy metal resistance genes on the chromosome and plasmid from ST34 isolates will challenge available therapeutic options. The presence of the colistin resistance gene (mcr-1, mcr-3, and mcr-5) with the multidrug-resistant phenotype in ST34 has spread across different countries, and most of the mcr-1 genes in ST34 isolates were detected in plasmid type IncHI2 followed by IncI2, and IncX4. Together, mcr-carrying S. Typhimurium ST34 may become a new pandemic clone. The fast detection and active surveillance in community, hospital, animal herds, food products and environment are urgently warranted.Entities:
Keywords: Colistin; Multidrug resistance; ST34; Virulence; mcr gene
Year: 2019 PMID: 31466338 PMCID: PMC6780495 DOI: 10.3390/microorganisms7090298
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Figure 1Emergence of global pandemic clone sequence type 34 (ST34) as compared to the “traditional” clone ST19 from 35,963 Salmonella Typhimurium isolates of the Enterobase [16]. Comparative analysis of number of isolates of ST19 and ST34 reported since 1890 till date shows that the increase in number of ST34 isolates in recent years.
Figure 2Global distribution of Salmonella Typhimurium ST34-carrying mobile colistin resistance (mcr)-1, mcr-3, and mcr-5 colistin resistance genes [9,10,11,12,17,18,19,20,21,22,23,24,25,26]. This also shows the different sample sources from where mcr-carrying bacterial strains were obtained from different countries. In the non-red marked countries, no cases of Salmonella Typhimurium ST34-carrying mcr genes were reported.
A comparative analysis of the percentage (%) of isolates of ST19 and ST34 from 35,963 Salmonella Typhimurium isolates of the Enterobase [16] shows the increase in the % of ST34 isolates in recent years.
| Years | % ST19 isolates | % ST34 Isolates |
|---|---|---|
|
| 100 | 0 |
|
| 100 | 0 |
|
| 100 | 0 |
|
| 100 | 0 |
|
| 100 | 0 |
|
| 100 | 0 |
|
| 100 | 0 |
|
| 98.38449 | 1.615509 |
|
| 96.35258 | 3.647416 |
|
| 95.56804 | 4.43196 |
|
| 90.86271 | 9.137291 |
|
| 63.74658 | 36.25342 |
|
| 64.14868 | 35.85132 |
|
| 55.09771 | 44.90229 |
|
| 50.5104 | 49.4896 |
|
| 54.48694 | 45.51306 |
|
| 60.84259 | 39.15741 |
|
| 43.78029 | 56.21971 |
|
| 43.76435 | 56.23565 |
Characteristics of the mcr-positive Salmonella Typhimurium monophasic clone ST34 found in different studies worldwide.
| Year of Publication | Country | Year of Sampling | Colistin MIC | Host | Sample Source | Sample Type | No. of Samples | No. of | No of | Plasmid Type Detected | Comments | Travel History | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016 | China [ | 2007–2015 |
| 16 mg/L | Animals | Duck, chicken, swine | Faecal | 276 | 22 | 5 | IncI2, IncHI2 | ||
| 2016 | England and Wales [ | 2012–2015 |
| 4–8 mg/L | Human | Human | Faeces | >24,000 | 17,684 | 4 | IncX4, IncHI2 | Thailand, Cambodia | |
| 2016 | Portugal [ | 2002–2015 |
| 4–8 mg/L | Human and Animals | Faeces/blood, Pork meat/carcass | 1010 | 1010 | 11 | IncHI2, IncX4 | Carried metal tolerance genes, (carrying | ||
| 2017 | Denmark [ | 2009–2017 | Human | Human | Stool, blood or urine | 2500 | 10 [1 ( | IncHI2A, IncHI2, IncN, TrfA, IncQ1, ColRNAI, IncA/C2, IncFII, IncX1, IncFIC(FII), IncI2 | Four of the patients had travelled to Thailand and one to Vietnam before onset of disease; three patients had unknown travel history. | ||||
| 2017 | China [ | 2013–2014 |
| 1–2 mg/L | Animals | Pigs | Cecum | 1780 | 142 | 19 | IncHI2 | ||
| 2017 | China [ | 2014 |
| 4 mg/L | Human | Human | Rectal swab | 1 | 1 | IncP | |||
| 2017 | Columbia [ | 2012–2016 |
| Human | Human | Stool, urine | 5887 | 13 | 3 | ColpVC, IncQ1, IncFIA, IncHI1A, IncHI1B | |||
| 2018 | Australia [ | 2016–2017 |
| 4 mg/L | Humans and animals | Human, pigs | 971 | 80 | 56 | The isolate from the case-patient who travelled to Vietnam | |||
| 2018 | Canada [ | 2013 |
| >4 mg/L | Human | Human | Faecal | 1 | 1 | IncHI2 | Man with previous travel history to Thailand | ||
| 2018 | China [ | 2014 |
| 8 mg/L | Animals | Pigs | Prepared pork that is ready-to-eat | 3200 | 30 | 1 | IncHI2, IncHI2A | ||
| 2019 | China [ | 2007– 2016 |
| 8 mg/L | Human | Human | Faeces | 62 | 62 | 3 | IncI2, IncHI2 | Patients with infectious diarrhoea. 2 were infants and the other was 15 years old. | |
| 2019 | China [ | 2006–2016 |
| 4–8 mg/L | Human | Human | Faeces | 134868 | 12053 | 37 | IncHI2, IncI2, IncX4 | Among the 37 patients infected with | |
| 2019 | Germany [ |
| 4 mg/L | animals | pigs | Faeces and meat | 315 | 8 | ColE-like, IncX1 | ||||
| 2019 | USA [ | 2014–2016 |
| >4 mg/L | Human | Human | Faecal | 100 | 1 | IncHI2 | 18 years old man with previous travel history to China |
Antibiotic resistance pattern, antibiotic resistance genes, virulence resistance-encoding genes and metal resistance genes found in mcr-positive ST34 isolates in different studies. NA = Not available.
| References | Antibiotic Resistance Phenotype | Antibiotic Resistance Genes | Virulence Resistance-Encoding Genes | Metal Resistance Genes | |
|---|---|---|---|---|---|
| [ |
| Colistin, β-Lactam, fluoroquinolone | NA | NA | |
| [ |
| Colistin, ampicillin, gentamicin, streptomycin, sulfamethoxazole; tetracycline; chloramphenicol; ciprofloxacin; pefloxacin, trimethoprim | NA | ||
| [ |
| Colistin, nalidixic acid, olaquindox, ampicillin, streptomycin, gentamicin, florfenicol, tetracycline, trimethoprim-sulfamethoxazole | NA | NA | |
| [ |
| Colistin, ampicillin, streptomycin, florfenicol, tetracycline, sulfamethoxazole/trimethoprim, gentamicin | NA | NA | |
| [ |
| Colistin, tetracycline, ampicillin, nalidixic acid, colistin, chloramphenicol, cephalothin, and cefoxitin, ciprofloxacin | NA | NA | |
| [ |
| Colistin, ampicillin, tetracycline, nalidixic acid, erythromycin, chloramphenicol, trimethoprim-sulfamethoxazole | NA | NA | |
| [ |
| Colistin, cefotaxime, cefepime, sulfamethoxazole/trimethoprim, ciprofloxacin | NA | NA | |
| [ |
| Colistin, streptomycin, amoxicillin/clavulanic Acid, trimethoprim/sulfamethoxazole, tetracycline, chloramphenicol, florfenicol, nalidixic acid, |
|
| |
| [ |
| Colistin, ampicillin, tetracycline, nalidixic acid, chloramphenicol, cefotaxime, cefazolin, trimethoprim/sulfamethoxazole, cefuroxime, cefepime, gentamicin, ciprofloxacin, azithromycin, cefoxitin, ceftazidime, cefotaxime/clavulanic acid, ceftazidime/clavulanic acid, ceftazidime | NA | NA | |
| [ | Colistin, aminoglycoside, β-Lactam, fluoroquinolone, sulfonamide, tetracyclines, florfenicol, | NA | NA | ||
| [ |
| Colistin, aztreonam, cefotaxime, ceftazidime, cefepime, chloramphenicol, gentamicin, kanamycin, trimethoprim/sulfamethoxazole, tetracycline | NA | NA | |
| [ |
| Colistin, fluoroquinolone, trimethoprim, aminoglycosides, β-lactams, sulfonamides | NA | NA | |
| [ |
| Colistin, polymyxin, ampicillin, amoxicillin-clavulanic acid, ceftiofur, ticarcillin/clavulanic acid, nalidixic acid, ciprofloxacin, chloramphenicol, sulfisoxazole, tetracycline, minocycline, doxycycline, trimethoprim-sulfamethoxazole, gentamicin, tobramycin, streptomycin | NA | NA | |
| [ |
| Colistin, ampicillin; sulfamethoxazole; tetracycline; trimethoprim; chloramphenicol | NA | NA |